Fresenius earnings calendar in focus, shares on Xetra watched by analysts

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 07:37.

Fresenius SE & Co. KGaA (DE0005785604) enters the week with investors looking toward the next earnings dates and the current analyst stance on the Xetra-listed healthcare stock. The DAX group keeps an updated financial calendar for its half-year and full-year figures on its investor relations pages, which anchor expectations for the coming months Fresenius financial calendar.

What analysts currently say

The consensus picture for Fresenius remains relatively stable across major broker platforms, with several international banks such as Deutsche Bank and UBS covering the stock and regularly updating their recommendations and price targets based on quarterly trends MarketScreener analyst overview for Fresenius. On Xetra, Fresenius stock is widely followed as a core healthcare component of the DAX index, which often makes broker rating changes and guidance updates visible in trading volumes.

Large houses typically look closely at Fresenius Helios hospital performance, Fresenius Kabi margins and the progress of the group transformation program when updating their models and target prices. Recent analyst notes have highlighted the importance of cost control, portfolio streamlining and leverage reduction for the group, with the financing structure and cash generation remaining central themes in valuation discussions.

Upcoming dates and earnings focus

Fresenius publishes its half-year and quarterly reports on fixed dates in its financial calendar, which investors use to position around earnings and guidance updates. The company typically reports second-quarter and first-half numbers in late summer and presents full-year results in the first quarter of the following year, accompanied by an outlook for group sales growth and adjusted EBIT development Fresenius events and presentations.

In addition to the main earnings releases, Fresenius often hosts conference calls and capital market events where management discusses organic growth in its operating segments, efficiency measures and capital allocation. These forums usually provide the data points that analysts incorporate into updated models, including assumptions on hospital occupancy, product mix in the infusion therapy and clinical nutrition businesses and the expected impact of cost inflation in staff and materials.

How Fresenius earns its money

Fresenius generates most of its revenue through healthcare services and products across several divisions, including Fresenius Helios hospitals, Fresenius Kabi pharmaceuticals and nutrition, and Vamed in project business. The group focuses on acute care, infusion therapy, clinical nutrition, generic intravenous drugs and related services for hospitals and other healthcare facilities.

Where the stock trades today

Fresenius shares trade on Xetra in euros as part of the DAX index; the current price and market capitalization can be followed via the Xetra order book and exchange data providers during regular trading hours.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.